Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.
about
Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling.The sGC activator BAY 60-2770 has potent erectile activity in the rat.Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock.Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Stimulators of soluble guanylyl cyclase: future clinical indicationsSoluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?Direct sGC activation bypasses NO scavenging reactions of intravascular free oxy-hemoglobin and limits vasoconstriction.Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension.Analysis of responses to glyceryl trinitrate and sodium nitrite in the intact chest rat.Peroxynitrite has potent pulmonary vasodilator activity in the rat.Relaxant effect of a metal-based drug in human corpora cavernosa and its mechanism of action.Vascular dysfunctions in the isolated aorta of double-transgenic hypertensive mice developing aortic aneurysm.
P2860
Q34179857-A5BA6C8A-86D1-4F2E-90E7-601C2EC76DF1Q34720361-53DE0B73-72A0-4022-B7E1-5297EEDBE930Q35010064-348B7D9F-9C7E-40EB-96CA-05DF8F4B0C16Q35075847-78CA6781-2A67-44BF-B76B-E4B0BB5EEFC3Q36532454-E17C9DDF-EE21-4056-AB1A-68B9D5FD967FQ36923923-248C680B-0E34-489C-9996-B02A08616DF4Q37734554-410BA280-7CC1-4224-900E-C0AA688B9508Q38000562-73BDD364-AE58-444F-B74B-3FF757866143Q38093420-209556D7-2860-45B7-B7F7-84EE06DB9613Q38818645-9D38925C-F5EB-4D52-B6E9-FF85EF2F47F6Q41894813-42E4010B-EB51-450F-806C-AE341F45EABBQ42244904-148273A3-00FC-4431-BE12-5E571C8BF4F1Q42502151-4FA8BDC4-0E90-4C40-99C5-61B3F34ECE10Q47977733-E8A6A9E1-C1D5-459A-A97C-EFF0E0FBAF56Q53462040-34BF6A0B-34C6-4D26-B6D3-391C33BB9FE3Q54185546-3CFA6860-EEB4-45A3-A1DB-C0A2FD54C81C
P2860
Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pulmonary and systemic vasodil ...... are modulated by nitric oxide.
@ast
Pulmonary and systemic vasodil ...... are modulated by nitric oxide.
@en
Pulmonary and systemic vasodil ...... are modulated by nitric oxide.
@nl
type
label
Pulmonary and systemic vasodil ...... are modulated by nitric oxide.
@ast
Pulmonary and systemic vasodil ...... are modulated by nitric oxide.
@en
Pulmonary and systemic vasodil ...... are modulated by nitric oxide.
@nl
prefLabel
Pulmonary and systemic vasodil ...... are modulated by nitric oxide.
@ast
Pulmonary and systemic vasodil ...... are modulated by nitric oxide.
@en
Pulmonary and systemic vasodil ...... are modulated by nitric oxide.
@nl
P2093
P2860
P1476
Pulmonary and systemic vasodil ...... are modulated by nitric oxide.
@en
P2093
Adeleke M Badejo
Bobby D Nossaman
Chandrika B Kannadka
Edward A Pankey
Manish Bhartiya
Philip J Kadowitz
Subramanyam N Murthy
Vaughn E Nossaman
P2860
P304
P356
10.1152/AJPHEART.01101.2009
P577
2010-07-16T00:00:00Z